| 401 |
27056542 | Incretin-based Therapies for Type 2 Diabetes. | 2008 |
2 |
| 402 |
30764059 | Sitagliptin: an oral agent for glucose control. | 2008 Nov |
2 |
| 403 |
17190843 | Rationale for dipeptidyl peptidase 4 inhibitors: a new class of oral agents for the treatment of type 2 diabetes mellitus. | 2007 Jan |
1 |
| 404 |
17244786 | The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients. | 2007 Apr |
1 |
| 405 |
17300591 | Dipeptidyl peptidase-IV inhibitors: a major new class of oral antidiabetic drug. | 2007 Mar |
1 |
| 406 |
17300594 | Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes. | 2007 Mar |
1 |
| 407 |
17303799 | Effects of dipeptidyl peptidase-4 inhibition on gastrointestinal function, meal appearance, and glucose metabolism in type 2 diabetes. | 2007 May |
2 |
| 408 |
17352676 | Dipeptidyl peptidase IV inhibitors: the next generation of new promising therapies for the management of type 2 diabetes. | 2007 |
1 |
| 409 |
17387446 | Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. | 2007 Jun |
1 |
| 410 |
17407650 | Pancreatic islet dysfunction in type 2 diabetes: a rational target for incretin-based therapies. | 2007 Apr |
1 |
| 411 |
17486328 | The influence of hepatic impairment on the pharmacokinetics of the dipeptidyl peptidase IV (DPP-4) inhibitor vildagliptin. | 2007 Jul |
1 |
| 412 |
17519080 | Effect of the novel oral dipeptidyl peptidase IV inhibitor vildagliptin on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. | 2007 May |
2 |
| 413 |
17593276 | Dipeptidyl peptidase 4 inhibition and vildagliptin therapy for type 2 diabetes. | 2007 Aug |
2 |
| 414 |
17656620 | Dose proportionality and the effect of food on vildagliptin, a novel dipeptidyl peptidase IV inhibitor, in healthy volunteers. | 2007 Sep |
1 |
| 415 |
17698900 | The dipeptidyl peptidase 4 inhibitor vildagliptin does not accentuate glibenclamide-induced hypoglycemia but reduces glucose-induced glucagon-like peptide 1 and gastric inhibitory polypeptide secretion. | 2007 Nov |
1 |
| 416 |
17724014 | The pathophysiologic role of incretins. | 2007 May |
1 |
| 417 |
17877545 | The DPP-4 inhibitor vildagliptin: robust glycaemic control in type 2 diabetes and beyond. | 2007 Sep |
2 |
| 418 |
17940427 | Dipeptidyl peptidase-4 inhibitors and the management of type 2 diabetes mellitus. | 2007 Apr |
1 |
| 419 |
18052023 | 8-(3-(R)-aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetes. | 2007 Dec 27 |
1 |
| 420 |
18084670 | DPP-4 Inhibitors and Combined Treatment in Type 2 Diabetes: Re-evaluation of Clinical Success and Safety. | 2007 Fall |
1 |
| 421 |
18217246 | Clinical management strategies for type 2 diabetes. | 2007 Dec |
2 |
| 422 |
16442340 | Applications of dipeptidyl peptidase IV inhibitors in diabetes mellitus. | 2006 |
1 |
| 423 |
16625820 | Dipeptidyl peptidase-IV inhibitors can restore glucose homeostasis in type 2 diabetics via incretin enhancement. | 2006 Apr |
2 |
| 424 |
17160910 | Dipeptidyl peptidase IV (DPP IV) inhibitors: A newly emerging drug class for the treatment of type 2 diabetes. | 2006 Dec |
1 |
| 425 |
15770466 | Dipeptidyl peptidase inhibitors as new drugs for the treatment of type 2 diabetes. | 2005 Apr |
1 |
| 426 |
15797249 | Probing prime substrate binding sites of human dipeptidyl peptidase-IV using competitive substrate approach. | 2005 Apr 15 |
1 |
| 427 |
15864535 | Hyperglycaemia increases dipeptidyl peptidase IV activity in diabetes mellitus. | 2005 Jun |
1 |
| 428 |
15978877 | Type 2 diabetes--therapy with dipeptidyl peptidase IV inhibitors. | 2005 Aug 1 |
3 |
| 429 |
16046120 | Diprolyl nitriles as potent dipeptidyl peptidase IV inhibitors. | 2005 Sep 15 |
2 |
| 430 |
16929363 | Biologic actions and therapeutic potential of the proglucagon-derived peptides. | 2005 Nov |
2 |
| 431 |
15032621 | CD26/dipeptidyl peptidase IV: a regulator of immune function and a potential molecular target for therapy. | 2004 Mar |
2 |
| 432 |
15126524 | Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. | 2004 May |
2 |
| 433 |
12517256 | Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes. | 2003 Jan |
1 |
| 434 |
14511643 | Dipeptidyl peptidase-IV expression and activity in human glomerular endothelial cells. | 2003 Oct 10 |
3 |
| 435 |
14514604 | Enhancing incretin action for the treatment of type 2 diabetes. | 2003 Oct |
2 |
| 436 |
14664713 | Novel dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1(7-36)amide have preserved biological activities in vitro conferring improved glucose-lowering action in vivo. | 2003 Dec |
1 |
| 437 |
15765627 | Harnessing the therapeutic potential of glucagon-like peptide-1: a critical review. | 2002 |
4 |
| 438 |
11284388 | Peptide truncation by dipeptidyl peptidase IV: a new pathway for drug discovery? | 2001 |
1 |
| 439 |
11394909 | Improved glucose tolerance via enhanced glucose-dependent insulin secretion in dipeptidyl peptidase IV-deficient Fischer rats. | 2001 Jun 8 |
1 |
| 440 |
10872532 | Effect of ageing and diabetes on glucose-dependent insulinotropic polypeptide and dipeptidyl peptidase IV responses to oral glucose. | 2000 May |
1 |
| 441 |
10588446 | Dipeptidyl-peptidase IV (CD26)--role in the inactivation of regulatory peptides. | 1999 Nov 30 |
2 |
| 442 |
9792533 | Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes. | 1998 Nov |
1 |